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Abstract: Angiogenesis is important in development, maintenance and progression of haematological malignancies. Some
clinical observations have indicated that in non-Hodgkin’s lymphoma (nHL) tumour microvessel density (MVD) may correlate
with tumour staging and outcome. The aim of the study was to examine relationship between MVD as a parameter of tumour
angiogenesis measured by expression of CD34 and the grade of nHL histological malignancy as determined by REAL
classification. 40 lymph node samples of patients with newly diagnosed nHL (17 women, 23 men; aged 48-70 yrs, median age
64 yrs; stage III and IV) and treated at the Department of Haematology, Wrocław Medical University in 1999-2002 were fixed
in 10% buffered formalin and embedded in paraffin. In all the studied cases, sections were incubated with antibodies against
CD34. The slides were stained with hematoxylin and eosin and evaluated histopathologically. Patients were divided into two
groups according to histological malignancy: indolent nHL (19 patients) and aggressive nHL (21 patients). Mean MVD
measured by expression of CD34 in aggressive and indolent nHL groups amounted to 19.45±11.24 vessels/0.375 mm2 and
21.7±12.4 vessels/0.375 mm2, respectively. Statistical analysis of microvessel staining demonstrated no correlation between
tumour MVD and grade of histological malignancy in lymph nodes of nHL patients. Nevertheless, angiogenesis observed in
nHL provides rationale for use of angiogenesis inhibitors in lymphoma therapy.
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Introduction 
In recent years, the role of angiogenesis (neovasculari-
sation) in neoplastic diseases, especially in growth of
solid tumours, has been increasingly studied. There are
some data that neovascularisation may be important in
development, maintenance and progression of haemato-
logical malignancies. Some clinical observations have
indicated that tumour microvessel density (MVD)
measured by CD34, CD31 antigen or von Willebrand
factor (vWF) expression is increased in lymphoprolif-
erative disorders and correlate with tumour staging and
outcome [1, 7, 8, 10, 11, 12, 18, 21]. Higher microvas-
cular density and increased serum levels of proan-
giogenic factors such as vascular endothelial growth
factor (VEGF) or basic fibroblasts growth factor (bFGF)
have been reported in chronic lymphocytic leukemia,
multiple myeloma and non-Hodgkin B-cell lymphomas
(nHL) [10, 19]. nHL are heterogenous group of malig-
nant neoplasms with different origin and clinical char-
acteristics. In terms of clinical aggressiveness nHLs may
be divided in two groups: agressive and indolent lym-
phomas.
The aim of the study was to examine the relationship
between MVD as a parameter of tumour angiogenesis
measured by expression of CD34 and the grade of nHL
histological malignancy as determined by REAL classi-
fication. 
Materials and methods
Angiogenesis was measured in 40 randomly selected adult patients
with non-Hodgkin’s lymphoma diagnosed and treated at the Depart-
ment of Haematology, Wrocław Medical University in 1999-2002.
The patients with nHL included 17 women and 23 men, aged 48-70
yrs (median 64 yrs). All patients had active disease at stage III and
IV. Clinical data are shown in Table 1. Clinical staging was done
according to the Ann Arbor classification system [9]. Histological
classification was not reviewed in conjunction with the present study,
but 19 lymphomas had been classified as indolent and 21 as ag-
gressive nHL according to the REAL classification [6] by a patho-
logist with a profound experience in lymphoms. Samples of the
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studied lymphomas were fixed in 10% buffered formalin and em-
bedded in paraffin. The slides were stained with hematoxylin and
eosin and evaluated histopathologically. 
Deparaffinised sections were boiled in citrate buffer to unmask
antigenic determinants. In all studied cases sections were incubated
with antibodies against CD34 (Class II, Clone QBEnd 10, DAKO,
Denmark). The DAKO Fast Red Substrate System was used as a
substrate and chromogen in immunocytochemical staining proce-
dures utilizing alkaline phosphatase. In each case the control was
included, in which the specific antibody was omitted. For the evalu-
ation of microvessel density (MVD), slides were scanned in the light
microscope at × 40 magnification and three areas of maximal MVD,
so-called "hot spots" were identified. In each hot spot, microvessels
(capillaries and small venules) were counted at × 400 magnification
by two investigators (each field representing an area of 0.375 mm2).
For each slide, the mean number of microvessels from these three
areas, including results obtained by two investigators, per 0.375 mm2
was calculated. Statistical analysis was made using the Mann-Whit-
ney U-test. Differences were considered statistically significant at
p<0.05. 
Results and discussion
The immunocytochemical reactions demonstrated a
variable intensity of staining in individual tumours.
CD34 showed both the membrane and cytoplasmic lo-
calisation (Fig. 1). Mean MVD in aggressive and indol-
ent nHL groups amounted to 19.45±11.24 vessels/0.375
mm2 and 21.7±12.4 vessels/0.375 mm2, respectively.
Statistical analysis showed no significant differences
between both nHL groups.
Angiogenesis plays a key role in tumour growth,
invasiveness and progression. After tumours switch
from the prevascular to the vascular and invasive phase,
they stimulate growth of new capillary blood vessels to
guarantee an adequate supply of oxygen and nutrients to
their proliferating cells. CD34, a myeloid progenitor cell
antigen also present in endothelial cells, is detectable in
all types of endothelium [5]. The monoclonal antibody
against CD34 reacts with endothelium of arteries and
venules, and has been found to stain more intensely
capillary endothelium [4]. It has been used for the diag-
nosis of vascular tumours and detection of small vessel
proliferation representing angiogenesis [17]. In this
study, we used data obtained from CD34 staining, since
this procedure was highly sensitive for endothelium and
produced the lowest background staining. 
There are some clinical observations indicating that
tumour MVD and expression of vascular endothelial
growth factor (VEGF) correlate with tumour staging and
outcome in solid cancers and lymphoid neoplasms. High
pretreatment serum VEGF concentration is associated
with poor outcome in nHL patients [16]. Ribatti et al.
reported increased capillary proliferation in the lymph
node biopsies of high grade nHL. MVD has been shown
to correlate with the biological behaviour in nodal B-cell
nHL and the frequency of nHL tissue microvessels
increases simultaneously with pathological progression
[13, 14, 19]. On the other hand, according to Ridell and
Norrby [15] MVD is higher in the involved lymph nodes
of patients with small lymphocytic lymphoma but the
number of blood vessels does not correlate with the
grade of tumour. There was no correlation between
tumour MVD and response to chemotherapy in patients
with diffuse large B-cell lymphoma [3]. Arias et al. [2]
found a statistically significant difference in MVD
Table 1. Clinical data of patients with non-Hodgkin lymphoma
(nHL) according to REAL classification
nHL classification number of patients
AGRESSIVE nHL 21
Diffuse large B cell
Follicular grade 3
Mantle cell
15
 2
 4
INDOLENT nHL 19
Small lymphocytic
Lymphoplasmocytoid
Marginal zone
Follicular grade 1, 2
 7
 6
 1
 5
Fig. 1. Microvessels in lymph node of patient with nHL highlighted
by antibodies against CD34: a - × 200; b - × 400.
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measured by immunostaining with anti-Factor VIII anti-
body between low and high grade nHL, when classified
in either the Working Formulation (WF) or the Kiel
Classification. However, the same authors found no
differences between WF of high and intermediate lym-
phomas. 
Our data demonstrate that there is no correlation
between tumour MVD revealed by CD34 staining and
grade of histological malignancy in lymph nodes of nHL
patients classified according to REAL classification. It
must be emphasised that the degree of angiogenesis may
vary between patients, over time, and in relation to the
disease status of the site biopsied [20]. Nevertheless,
angiogenesis observed in nHL provides rationale for the
use of angiogenesis inhibitors in lymphoma therapy.
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